Femasys Inc. (FEMY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Instruments & Supplies Branche. Der Hauptsitz des Unternehmens ist in Suwanee, GA, United States. Der aktuelle CEO ist Kathy Lee-Sepsick.
FEMY hat IPO-Datum 2021-06-18, 69 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $12.63M.
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
